Stock Events

Stock Events

Kezar Life Sciences 

$7.29
41
-$0.07-0.95% Friday 19:59
+$0.17+2.33%Friday 20:50Pre-market

Statistics

Day High
7.47
Day Low
7.27
52W High
7.55
52W Low
3.53
Volume
616,015
Avg. Volume
87,859
Mkt Cap
53.38M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

6AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
-3.15
-2.36
-1.57
-0.78
Expected EPS
-1.05
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-167.47MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow KZR. It's not an investment recommendation.
Apple
7
AAPL
Realty Income
6
O
Tesla
6
TSLA
Amazon
6
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical focuses on enzyme replacement therapies, directly competing in the rare disease space similar to Kezar's focus.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals targets cystic fibrosis and other rare diseases, overlapping with Kezar's therapeutic areas.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals specializes in RNAi therapeutics for rare genetic diseases, competing in the same niche as Kezar.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is involved in gene editing for rare diseases, representing direct competition in innovative treatments.
Novartis
NVS
Mkt Cap292.35B
Novartis AG has a broad portfolio including treatments for autoimmune diseases and rare conditions, competing across several of Kezar's interest areas.
Biogen
BIIB
Mkt Cap32.28B
Biogen focuses on neurology and rare diseases, areas where Kezar Life Sciences is also aiming to develop treatments.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences has a diverse portfolio including oncology and inflammatory diseases, directly competing with Kezar's research focus.
AMGEN
AMGN
Mkt Cap233.78B
Amgen has a broad focus including treatments for cancer and autoimmune diseases, overlapping with Kezar's therapeutic areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals is known for its innovative treatments in areas like oncology and rare diseases, competing with Kezar's development pipeline.

About

Kezar Life Sciences, Inc. is a United States-based clinical-stage biopharmaceutical company focused on identifying and advancing novel small molecule therapies. Its mission is to address significant unmet medical needs in both immune-mediated diseases and various forms of cancer. The company's most advanced experimental drug is KZR-616, a specialized immunoproteasome inhibitor. This candidate is currently undergoing Phase 2 clinical evaluation for several conditions, including lupus nephritis, dermatomyositis, and polymyositis. Concurrently, KZR-616 is also in Phase 1b clinical trials for systemic lupus erythematosus and lupus nephritis. In its preclinical pipeline, Kezar is developing KZR-261, a pioneering first-in-class protein secretion inhibitor, as well as KZR-TBD, which is being investigated for its potential in oncology and immunology. The firm was founded in 2015 and is headquartered in South San Francisco, California.
Show more...
CEO
Dr. Christopher J. Kirk Ph.D.
Employees
55
Country
United States
ISIN
US49372L1008
WKN
000A40NJT

Listings

MU
DE
2KZ.MU
XNAS
US
KZR
BOATS
BOATS
KZR.BOATS

0 Comments

Share your thoughts

FAQ

What is Kezar Life Sciences stock price today?▼
The current price of KZR is $7.29 USD — it has decreased by -0.95% in the past 24 hours. Watch Kezar Life Sciences stock price performance more closely on the chart.
What is Kezar Life Sciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Kezar Life Sciences stocks are traded under the ticker KZR.
Is Kezar Life Sciences stock price growing?▼
KZR stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Kezar Life Sciences has showed a +90.84% increase.
What is Kezar Life Sciences market cap?▼
Today Kezar Life Sciences has the market capitalization of 53.38M
What is Kezar Life Sciences revenue for the last year?▼
Kezar Life Sciences revenue for the last year amounts to 0 USD.
What is Kezar Life Sciences net income for the last year?▼
KZR net income for the last year is -167.47M USD.
How many employees does Kezar Life Sciences have?▼
As of September 04, 2026, the company has 55 employees.
In which sector is Kezar Life Sciences located?▼
Kezar Life Sciences operates in the Health & Wellness sector.
When did Kezar Life Sciences complete a stock split?▼
The last stock split for Kezar Life Sciences was on October 30, 2024 with a ratio of 1:10.
Where is Kezar Life Sciences headquartered?▼
Kezar Life Sciences is headquartered in South San Francisco, United States.